SC
BMRN icon

SummitTX Capital’s BioMarin Pharmaceuticals BMRN Stock Holding History

SummitTX Capital’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.9M Sell
50,737
-39,895
-44% -$2.19M 0.07% 277
2026
Q1 		$5.12M Buy
90,632
+51,180
+130% +$2.98M 0.16% 153
2025
Q4 		$2.34M Buy
+39,452
New +$2.15M 0.07% 286
2025
Q3 		– Sell
-6,559
Closed -$361K – 767
2025
Q2 		$361K Buy
+6,559
New +$386K 0.02% 575

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SummitTX Capital's BMRN Position: Q2 2026 in Review

SummitTX Capital reduced its BioMarin Pharmaceuticals (BMRN) stake by 44% in Q2 2026, selling an estimated $2.19M and leaving 50,737 shares worth $2.9M. The position accounts for 0.07% of the portfolio, ranked #277.

SummitTX Capital first reported a position in BMRN in Q2 2025 and has held it in 4 quarters since. The position peaked at $5.12M in Q1 2026. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • SummitTX Capital held 50,737 shares of BioMarin Pharmaceuticals worth $2.9M as of Q2 2026.
  • SummitTX Capital sold 39,895 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.19M.
  • BioMarin Pharmaceuticals made up 0.07% of SummitTX Capital's portfolio in Q2 2026, its #277 holding.
  • SummitTX Capital first reported a position in BioMarin Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • SummitTX Capital's BioMarin Pharmaceuticals position peaked at $5.12M in Q1 2026.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.